Top Model (Scandinavian TV series)

Top Model is a Scandinavian reality television show, based on Tyra Banks' "America's Next Top Model". It was broadcast on TV3 in Denmark, Norway and Sweden by Viasat in 2005 and 2006. A second adaptation of the show featuring plus-sized models was produced by the network in 2016.
Format.
The competition was divided into three separate competitions: Denmark, Norway and Sweden. Each contest began with a group of twenty-something national semi-finalists that were narrowed down to nine national finalists in the first episode. Each episode, one contestant was eliminated, until there were just three contestants remaining in each competition. At that point, the three competitions would merge into one overall competition. The last contestant standing from each country competed in the finale, and from this group a winner was chosen.
The individual hosts for each country were Anne Pedersen in Denmark, Kathrine Sørland in Norway, and Mini Andén in Sweden. Andén left the show after the first two seasons and was replaced by Malin Persson for the third. The merged competition was hosted by Georgianna Robertson in season 1 and Cynthia Garrett in seasons 2 and 3.

Drospirenone/estetrol

Drospirenone/estetrol (E4/DRSP), sold under the brand names Estelle and Nextstellis among others, is a fixed-dose combination medication of drospirenone, a progestin, and estetrol, an estrogen, which is used as a combined birth control pill for the prevention of pregnancy in women. It is taken by mouth.
As of March 2021, it is approved in Canada and is pending approval in other countries. It was approved for medical use in the United States in April 2021.
Medical uses.
Drospirenone/estetrol is used as a combined birth control pill to prevent pregnancy in women.
Available forms.
In Canada it is available in the form of oral tablets containing 15mg estetrol and 3 mg drospirenone.
In the United States the tablets contain drospirenone 3mg and estetrol 14.2mg.
Pharmacology.
Pharmacodynamics.
Drospirenone/estetrol has a much lower impact on liver protein synthesis, including of sex hormone-binding globulin, angiotensinogen, and coagulation factors, than does ethinylestradiol/drospirenone.
Society and culture.
Legal status.
On 25 March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Lydisilka (estetrol/drospirenone), intended for oral contraception. The applicant for this medicinal product is Estetra SPRL. The CHMP also recommended the granting of a marketing authorisation for the medicinal product Drovelis (estetrol/drospirenone), intended for oral contraception. The applicant for this medicinal product is Gedeon Richter Plc.